Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yuce Bio Completes $43 Million Funding for Clinical Cancer Immunotherapy Testing

publication date: Aug 25, 2020

Shenzhen Yuce Biological completed a $43 million Series C round led by Yuanzhi Science & Technology Medical for its clinical testing of cancer immunotherapies. Yuce Bio has developed a new antigen detection and identification platform, a professional database for cancer immunology based on bioinformatics, and a large real-world research database of tumor immunodiagnosis. As part of its program, Yuce has developed YuceOne Plus®, the first in vitro diagnostic reagent that uses gene testing to evaluate the effectiveness of an immunotherapy drug regimen. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital